Introduction
Heart failure (HF) is a frequent disease in developed countries and is associated with increased mortality and morbidity, quality of life impairment, and heavy healthcare and economic burden. Data from the ESC-HF Pilot survey 1 conducted in 12 European countries showed post-discharge mortality and readmission rates at 1 year of 17.4% and 31.9%, respectively. More recent data confirmed the important clinical and economic burden of HF hospitalizations. 2, 3 Cardiac resynchronization therapy (CRT) has been shown to reduce mortality and rehospitalization in selected HF patients. 4, 5 A recent study from a real-world cohort showed that the risk of hospitalization remains high in recipients of implantable cardioverter defibrillators (ICDs) or biventricular defibrillators for cardiac resynchronization therapy (CRT-D) 6 . Remote monitoring (RM) of implantable cardiac devices can facilitate patient access to healthcare and prompt preventive actions to improve HF outcomes. Several studies demonstrated the safety of RM and its potential impact on patient management, such as the reduction of time to clinical decision, 7 -11 number of outpatient visits, 12 and inappropriate shocks. 13 Whether these benefits translate into improved clinical outcomes is still not clear.
The randomized MORE-CARE (MOnitoring Resynchronization dEvices and CARdiac patiEnts) trial was planned to evaluate whether RM may be of higher clinical and/or economic value compared with standard follow-up strategies in the management of systolic HF patients implanted with a CRT-D.
Methods

Study design and patient population
The MORE-CARE is an international, prospective, multicentre, randomized controlled trial involving 61 cardiology centres in nine countries overall, from Europe and Israel. The trial was designed in two phases to demonstrate that RM reduces the time from the onset of a clinically relevant event to clinical decision (Phase 1), and the incidence of all-cause deaths and major cardiovascular (CV) and device-related hospitalizations (Phase 2) compared with standard in-hospital care. Details of the study design and Phase 1 results have already been described. 10, 11 In brief, Phase 1 demonstrated that the median delay from device-detected events to clinical decisions was reduced in the remote group compared with the control group [2 (25th-75th percentile, 1-4) days vs. 29 (25th-75th percentile, 3-51) days, P = 0.004]. All patients had received de novo implant of a Medtronic CRT-D with wireless transmission capabilities within the last 8 weeks before enrolment. Randomization was stratified by centres and performed at enrolment using a centralized electronic system. Patients were randomized 1:1 to undergo remote checks alternating with in-office follow-ups (Remote arm) or in-office follow-ups alone (Standard arm).
The trial was registered at www.clinicaltrials.gov under number NCT00885677.
The study was approved by the Ethics Committee of all participating centres and was conducted in compliance with the Declaration of Helsinki. All patients signed a written informed consent. 
Device programming and diagnostic features
Patients in the Remote arm received a Carelink monitor for scheduled remote device checks, and automatic alerts for lung fluid accumulation (OptiVol ® ), atrial tachyarrhythmia (atrial tachycardia/fibrillation), and system integrity were enabled. In-office device checks were requested to re-arm alerts which had been temporarily inactivated due to previous transmissions. For both arms, audible alerts were disabled, except alerts for system integrity, low battery voltage, excessive charge time, and ventricular fibrillation detection/therapy off. Study flow charts were provided to investigators with the aim to suggest and guide patient remote management. 10 
Data collection
Clinical and device data were collected at enrolment and during scheduled remote checks/in-office visits. Patients in the Remote arm alternated remote checks with in-office visits every 4 months, while the Standard arm received in-office visits every 4 months. Additional data were collected in the case of unscheduled visits or automatic alerts, medical interventions, adverse events, and study deviations. Information about patient and caregiver travel (e.g. distance, time, transport) for in-office visits was also collected.
Study objectives
The primary objective of the MORE-CARE Phase 2 was to evaluate the impact of RM on reducing the 2-year incidence of a composite endpoint including mortality, CV and device-related hospitalizations. Owing to their higher impact on patient morbidity and healthcare costs, only hospitalizations longer than 48 h were included in this primary endpoint evaluation. Each reported event was adjudicated by an independent Event Adjudication Committee to evaluate whether it could be counted as a study endpoint. The Committee included three physicians not involved in the trial and blinded to investigational sites, patient identities, and randomization assignment.
The secondary endpoints were: (i) the utilization of healthcare resources for CV reasons, combining any duration of CV hospitalizations and CV emergency department (ED) admissions together with both scheduled and unscheduled outpatient visits; (ii) the number of hospitalizations, ED admissions, and outpatient visits separately; (iii) the costs related to utilization of healthcare resources for CV and device reasons both from the healthcare and from the patient perspective; and (iv) the safety of RM in CRT-D patient management.
The methods adopted for monetary valuations of healthcare costs are reported in the Supplementary material online (Table S1 ).
Sample size
The study sample size calculations have already been decribed. 10 In brief, sample size was calculated to compare the 2-year incidence of the composite endpoint, assuming an event rate of 30% in the Standard arm and a target of 20% relative hazard reduction in the Remote arm, with a power of 90% and a confidence interval (CI) of 95%. Up to seven interim analyses and the final analysis were planned at pre-specified time points to reach a maximum sample of 1720 patients. With an expected enrolment rate of 336 patients per year, the estimated study duration was ∼4 years. The protocol included the option to prolong or shorten the study duration in the case of a slower or faster rate of enrolment, respectively.
Statistical analysis
The analysis set was made up of all randomized patients and included data of the 2-year follow-up period. Crossovers between randomization arms were not admitted in the study design; consequently, data were analysed according to the per-protocol principle. Further details on statistical analysis are given in the Supplementary material online ( Table S1 ).
All tests were adjusted for centre and any unbalanced baseline characteristic. An alpha-level of 0.05 was considered for each test. All statistical analyses were performed using SAS 9.3 version software (SAS Institute Inc., Cary, NC, USA).
Early study closure
In July 2014, the Steering Committee decided to terminate the study prematurely because of a lower than expected enrolment rate (36 patients in the last months) leading to an unrealistic prolongation of the enrolment period. As a consequence, no additional patients were enrolled and ongoing patients were followed until 30 April 2015 to ensure a minimum follow-up of 8 months for the last patients.
Results
Recruitment and population description
From May 2009 to July 2014, a total of 918 patients were enrolled in the study. One patient withdrew before randomization, 462 patients were randomly assigned to the Remote arm, and 455 to the Standard arm ( Figure 1 ). Twenty-five and 27 patients from the Remote and Standard arm, respectively, were excluded from the analysis set for either unmet inclusion/exclusion criteria or missing . Characteristics of the 865 included patients were balanced between the study arms ( Table 1 ) except for gender, history of AF, and atrioventricular block. Mean age at enrolment was 66 ± 10 years, and 76% of patients were men. Forty-four per cent of patients had ischaemic heart disease, 27% had a history of AF, and 12% had a history of sustained ventricular arrhythmias. Mean LVEF was 27 ± 6%. Thirty-eight per cent of patients were in NYHA class II at the time of enrolment, with clinical improvement as compared with NYHA class before CRT-D device implantation (all the patients were in NYHA class III-IV before implant).
The median follow-up was 24 months for both arms, with an interquartile range (IQR) of 15-25 months and 14-26 months in the Remote and Standard arm, respectively. Total exposure time was 707 patient-years in the Remote arm and 696 patient-years in the Standard arm. All randomized patients who met the inclusion/exclusion criteria were included in the analysis until study exit or death. Follow-up compliance was 94% in both arms: 1806 (867 in-office visits) out of 1913 (877 in-office visits) in the Remote arm vs. 1789 out of 1912 in the Standard arm (P = 0.54).
Primary composite endpoint (deaths, cardiovascular or device-related hospitalizations)
Overall, 253 patients reached the primary composite endpoint, 130 (29.7%) in the Remote arm and 123 (28.7%) in the Standard arm: the Kaplan-Meier 2-year risk estimates were 34.3% (95% CI 29.7-39.4) and 32.7% (95% CI 28.2-37.8), respectively (P = 0.89, Figure 2 ). No significant differences were found in the individual components of the primary endpoint (all P > 0.05, Table 2 ). The most frequent component of the primary endpoint was CV hospitalizations, whose Kaplan-Meier 2-year estimates were 27.3% (95% CI 22.9-32.2) in the Remote arm and 26.7% (95% CI 22.4-31.6) in the Standard arm (P = 0.80).
During the course of the study, 74 patients died: 40 (9.2%) in the Remote arm and 34 (7.9%) in the Standard arm. The Kaplan-Meier 2-year mortality estimates were 11.2% (95% CI 8.3-15.1) and 9.4% (95% CI 6.8-12.9), respectively (P = 0.59). The 2-year CV mortality rates were 8.2% (95% CI 5.7-11.7) and 7.8% (95% CI 5.4-11.1), respectively (P = 0.87, Kaplan-Meier curve reported in the Supplementary material online, Figure S1 ).
Use of healthcare resources for cardiovascular reasons
The burden of healthcare resource utilization for CV reasons was 38% lower in the Remote vs. the Standard arm [incidence rate ratio (IRR) 0.62, 95% CI 0.58-0.66, P < 0.001, Figure 3] , with 2-year rates of 3.7 (95% CI 3.5-3.9) and 6.0 (95% CI 5.7-6.2) per 100 patients, respectively. As shown in Table 3 , 649 hospitalizations were reported, 337 in the Remote arm and 312 in the Standard arm. The all-cause hospitalization rates, estimated as the 2-year rate per 100 patients, were 96 (95% CI 86-106) and 90 (95% CI 80-100, p = 0.83), respectively. Hospitalizations for CV reasons were 197 (111 due to HF) and 200 (103 due to HF) in the Remote and Standard arm, respectively. During the study, there were 106 ED admissions ( Table 3 ) not followed by a hospitalization, with a significantly lower occurrence in the Remote arm (IRR 0.72, 95% CI 0.53-0.98, P = 0.04). As shown in Table 3 , RM led to a significant reduction in total visits (IRR 0.59, 95% CI 0.56-0.62, P < 0.001), with more frequent unscheduled visits compared with the Standard arm (IRR 2.80, 95% CI 2.16-3.63, P < 0.001). Figure 3 Two-year rates per randomization group of scheduled outpatient visits, unscheduled planned and unplanned outpatient visits, and cardiovascular emergency department admissions and hospitalizations. For each randomization group and type of visit, the total number of occurrences is displayed beside the corresponding bar. IRR incidence rate ratio.
Costs for cardiovascular and device-related events from the National Healthcare System perspective
Costs related to healthcare resource utilization for CV and device-related reasons are shown in Table 4 . When considering the estimated costs for the review of device transmissions in the Remote arm, the cost saving from RM was €2899 per 100 patients at 2 years ( 
Costs for visits and device checks from the perspective of the patient budget
Information about patient and caregiver travel to and from the hospital showed an average distance between patient's home and hospital of 52 km, and the average time required for a one-way journey was 50 min. In 66% of visits, patients were accompanied by a relative, and in 5% by an acquaintance or nurse or caregiver. The majority of journeys (77%) were made by car; other modes of transportation included local transport by bus (11%), taxi (6%), and train (3%). The estimated 2-year expenses for patient travelling 
<0.001
CI, confidence interval; ED, emergency department; FU, follow-up; HCU, healthcare resource utilization; IRR, incidence rate ratio. to the hospital were €373 in the Remote arm and €518 in the Standard arm (i.e. a cost saving of €145 resulting from RM).
Automatic alert transmissions
In the Remote arm, 5670 alerts were identified and 4683 (82.6%) were successfully transmitted. Among the 987 failed transmissions, 361 transmissions failed because the patients were already in the hospital. By excluding these transmissions, the successful transmission rate rose to 88.2%. Other reasons for transmission failure were: monitor set off, phone line connection problems, or patient's temporary absence from home.
Quality of life
The patient's quality of life was investigated by means of the Minnesota Living With Heart Failure Questionnaire. Baseline values were comparable between the Remote (26, IQR 12-49) and Standard (27, IQR 11-46, P = 0.46) arms. The changes in quality of life from baseline to 16-month follow-up were similar in the Remote arm (15, and Standard arm (10, IQR 3-26, P = 0.29). As reported in detail in the Supplementary material online ( Figure S1 ), in both groups quality of life significantly improved at follow-up vs. baseline (P < 0.001).
Safety issues
Adverse events analysis showed that clinical use of RM did not raise any safety issue: there were 55 adverse events related to the implanted system in the Remote arm and 53 in the Standard arm with 2-year rates of 15.6 (95% CI 11.9-20.3) and 15.2 (95% CI 11.6-19.9) per 100 patients, respectively (P = 0.92).
Discussion
Remote monitoring is proposed as a tool for changing the management of HF patients with an implanted device, 14 aiming to improve patient outcome, as well as to reduce the use of resources and costs for both healthcare systems and patients. The present study was focused on a specific population of patients with pre-implant NYHA class III-IV, expected to face a greater number of events and having complex and time-consuming follow-up needs.
Remote monitoring, mortality and cardiovascular hospitalizations
The present randomized controlled trial showed that, in patients with systolic HF and implanted with a CRT-D with automated alerts for pulmonary congestion and atrial arrhythmias, RM is not associated with a benefit on mortality or risk of CV or device-related hospitalization. These findings are in line with the results of a recent meta-analysis of 11 randomized controlled trials 15 that showed no significant effect of RM either on all-cause mortality or on cardiac mortality in HF patients implanted with cardiac implantable electrical devices. More recently, the OptiLink HF study 16 intrathoracic impedance and telemedicine-based HF disease management strategy, showing no effect of telemonitoring on all-cause death or CV hospitalizations in patients with moderate to severe HF and implanted with an ICD/CRT-D. The IN-TIME trial is the only study that showed a positive effect of RM on patient survival, with a reduced mortality in the remote arm, but without effects on hospitalizations for worsening of HF 17 . It is noteworthy that 1-year mortality in the Standard arm of IN-TIME was 1.8-fold that observed in the Standard arm of MORE-CARE (8.7% vs. 4.8%), thus indicating differences in patient population characteristics that may have affected the finding of a beneficial effect on hard outcomes.
Hospitalizations for HF accounted for only around one-third of all admissions in our study. Real-world data have shown that co-morbidities significantly and independently affect both all-cause and HF hospitalizations, 6, 18 and may therefore mitigate the impact of RM. It seems clear that, according to evidence from systematic reviews, 15 recent studies, 16 and the present trial, RM of HF patients, when applied for the purpose of disease management, does not significantly decrease hospital admissions. Nevertheless, our data show that RM with advanced diagnostics for HF is safe and does not compromise outcome. This is in contrast to the use of audible alerts for transthoracic impedance monitoring, which has been shown to increase HF hospitalizations and outpatient visits in the DOT-HF trial.
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Remote monitoring transmission reliability
An important aspect for widespread implementation of RM is reliability of transmissions. In our study, 88.2% of alerts were properly transmitted, which is an improvement compared with previous reports. 8, 16 This may be due to better patient education together with technical improvements and more experience with RM compared with earlier studies.
Healthcare resource utilization
In the present study, we decided to analyse clinical and economic benefits together, since both are relevant for the healthcare system. 20 The positive results found in the present study are related to a 41% reduction in scheduled outpatient visits, despite a small increase in unscheduled visits, but no increase in ED admissions. This net benefit has interesting implications for re-organization of care, with financial benefits for both the healthcare system and the patients. The reduction in scheduled outpatients visits appears important because most of device follow-ups are routine checks with no actionable events or device programming. 21 Economic analyses focusing on RM of cardiac devices are growing, but comparisons across studies are challenged by differences in study design and issues specific to this type of analysis, such as costing methodologies and the perspective adopted (societal, payer, or provider).
In the present study, RM had a favourable profile in terms of costs, from the perspective of both the healthcare system and that of the patient. This may be a valid reason for implementing RM despite the lack of impact on hard clinical outcomes. Moreover, RM may be more efficient than traditional in-office follow-up, with allocation of resources to other tasks. 21 A number of reports have evaluated resource use and costs related to RM. 22 -29 Reductions in staff time and associated costs have been consistently reported in several studies, 23, 29 with the exception of the EuroEco study, 22 where costs were comparable for device checks based on remote vs. conventional in-office visits.
Results related to costs for healthcare resource utilization are variable: Fauchier, 25 Raatikainen, 23 Zanaboni, 24 and Guédon-Moreau 26 reported or assumed savings (due to reduced visits or hospitalizations, and/or reimbursed transports), whereas Al-Khatib, 27 Burri, 28 and Heidbuchel 22 did not. This reflects the variable results of RM studies in terms of outcomes, including number of visits and hospitalizations. In a recent meta-analysis, Klersy et al. 15 reported that standard follow-up is associated with higher costs, in the range of 10-55%, as compared with RM, and that the benefit is likely to be due to a reduction in planned visits. Our findings are an additional contribution to the field with regard to savings that can be achieved from the perspective of the healthcare system. Furthermore, MORE-CARE has also shown a benefit in terms of patient costs related to transportation. Another randomized study (REM-HF 30 ) is going to assess RM in HF when applied to a large number of individuals at nine UK hospitals, taking into account clinical endpoints (all-cause death or unplanned hospitalization as the primary endpoint), as well as economic endpoints. The latter include the cost per quality-adjusted life years, with direct costs estimated from the National Health Service perspective. Both patients with CRT devices and patients with ICDs are included. 30 Finally, costs for performing RM were often not taken into account in previous economic analyses on RM. This may be linked to the absence of reimbursement in most countries. In MORE-CARE, savings in the RM arm were maintained despite taking into account payment for remote device management.
Limitations
Although the present study was underpowered to evaluate the primary endpoint because of premature termination, it provides some data to be evaluated according to the literature, which in general is in line with our findings, if the primary endpoint and its components are considered.
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The present analyses excluded some randomized subjects because those implanted with a CRT-D, or unable to use the CareLink System, were not considered in the analysis set. Despite having provided flow charts for managing specific alerts, clinical practice was likely to have varied between different study centres. This reflects daily practice and the complexity of HF management. Furthermore, automatic alerts for HF monitoring were programmed only for AF and thoracic impedance, with no activation for several parameters-heart rate variability, nocturnal heart rate, and patient activity-that have recently been the subject of investigation for improving prediction of HF worsening. 31 The economic benefit was based on some assumptions and on tariffs derived from the Italian context, where most of the patients were recruited (52.7%). 32 the extent of monetary savings that could be achieved may be underestimated by the current analysis. Finally, in our economic analysis we did not consider the perspective of the provider, but focused on that of the healthcare system and the patient.
Conclusions
In HF patients implanted with a CRT-D, RM did not reduce mortality or risk of CV or device-related hospitalization. Despite the lack of benefit on clinical outcomes, the use of RM had a positive impact on the use of healthcare resources, with a 41% reduction of in-office visits, without compromising patient safety. The favourable profile in terms of cost savings of RM vs. standard follow-up emerged from the perspective of the healthcare system as well as from that of the patient.
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